Comparison of the Effects of Standardized Chokeberry Extracts With Various Formulations on the Levels of Selected Markers Associated With Cardiovascular Disease

Randomized, double-blind, parallel study conducted under medical supervision on a group of 40 patients with known hypertension and/or hypercholesterolemia. Patients receive one of the investigational products or placebo for 6 weeks. Before and after the study, the following parameters are analyzed: extended lipid panel (total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), HDL and lipoprotein A, apolipoprotein Apo A1 and Apo B), levels of glucose, insulin, homocysteine, markers of kidney and liver function (alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), uric acid). Effects on blood pressure and anthropometric parameters are also being evaluated.

Inclusion criteria

• Women and men, 18-55 years old
• Patients with known: hypertension or hypercholesterolemia,
• Patients on hypotensive or hypolipemic therapy for at least 6 months prior to study enrollment
• Signed informed consent

Exclusion criteria

• Intake of supplements containing plant extracts, polyphenols or anthocyanins,
• Intake of supplements with antioxidant properties,
• Participation in another clinical trial,
• Women who are pregnant, planning to become pregnant during the study, or breastfeeding,
• Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant,
• Patients receiving glucocorticosteroids, anti-allergic drugs, non-steroidal anti-inflammatory drugs in exacerbations of chronic disease.
• Patients with signs of inflammation such as increased body temperature, redness, swelling, pain.
• Patients who have not given written consent to participate in the study.